Just halfway through the year, 2019 has been busy for biosimilars, with new guidance and approvals but also the loss of a big advocate of biosimilars from the FDA.
Just halfway through the year, 2019 has been busy for biosimilars, with new guidance and approvals but also the loss of a big advocate of biosimilars from the FDA. In this episode of Managed Care Cast, Kelly Davio, senior editor of The Center for Biosimilars®, a sister site of The American Journal of Managed Care®, discusses new approvals; what the loss of Scott Gottlieb, MD, as FDA commissioner means; the reality of pay-for-delay deals; and more.
Editor's note: since this conversation was recorded, 2 additional biosimilars, both anticancer agents, have launched in the United States. Learn more here.
Learn more about biosimilars at centerforbiosimilars.com.
Listen above or through one of these podcast services:
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen